ExploreWatchlistsPricing
  1. JP-listed companies
  2. Cuorips Inc.
  3. Financials
  4. Stockholders' equity

Cuorips Inc. (4894)

Market cap
¥35.3B
P/E ratio
-25.8x
Qualips develops regenerative medicine treatments using human iPS cells, specializing in cardiac muscle cell sheets for severe heart failure patients.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndStockholders' equity (Million JPY)YoY (%)
Mar 31, 20264,769-13.76%
Mar 31, 20255,530-7.59%
Mar 31, 20245,984+73.26%
Mar 31, 20233,454-11.34%
Mar 31, 20223,896-7.74%
Mar 31, 20214,222+462.85%
Mar 31, 2020750

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat